HK1046002B - 免疫调节性类固醇，特别是16α-溴表雄酮的半水合物 - Google Patents

免疫调节性类固醇，特别是16α-溴表雄酮的半水合物 Download PDF

Info

Publication number
HK1046002B
HK1046002B HK02106613.2A HK02106613A HK1046002B HK 1046002 B HK1046002 B HK 1046002B HK 02106613 A HK02106613 A HK 02106613A HK 1046002 B HK1046002 B HK 1046002B
Authority
HK
Hong Kong
Prior art keywords
infection
groups
compounds
hemihydrate
hydroxy
Prior art date
Application number
HK02106613.2A
Other languages
English (en)
Chinese (zh)
Other versions
HK1046002A1 (en
Inventor
克拉伦斯‧纳撒尼尔‧阿勒姆
克拉倫斯‧納撒尼爾‧阿勒姆
詹姆斯‧马丁‧弗林克
路易斯‧丹尼尔‧多斯安若斯‧德卡瓦略
詹姆斯‧馬丁‧弗林克
威廉‧赫吉
帕特里克‧T‧普伦德加斯特
路易斯‧丹尼爾‧多斯安若斯‧德卡瓦略
克里斯托弗‧L‧雷丁
克鲁帕卡‧保罗‧撒迪孔达
拉塞尔‧尼尔‧弗农
帕特里克‧T‧普倫德加斯特
克魯帕卡‧保羅‧撒迪孔達
拉塞爾‧尼爾‧弗農
Original Assignee
Harbor Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harbor Therapeutics, Inc. filed Critical Harbor Therapeutics, Inc.
Publication of HK1046002A1 publication Critical patent/HK1046002A1/xx
Publication of HK1046002B publication Critical patent/HK1046002B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK02106613.2A 1999-03-23 2000-03-23 免疫调节性类固醇，特别是16α-溴表雄酮的半水合物 HK1046002B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US12605699P 1999-03-23 1999-03-23
US60/126,056 1999-03-23
US14002899P 1999-06-16 1999-06-16
US60/140,028 1999-06-16
US41490599A 1999-10-08 1999-10-08
US09/414,905 1999-10-08
US16404899P 1999-11-08 1999-11-08
US60/164,048 1999-11-08
PCT/US2000/007883 WO2000056757A1 (en) 1999-03-23 2000-03-23 Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone

Publications (2)

Publication Number Publication Date
HK1046002A1 HK1046002A1 (en) 2002-12-20
HK1046002B true HK1046002B (zh) 2006-10-20

Family

ID=27494614

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02106613.2A HK1046002B (zh) 1999-03-23 2000-03-23 免疫调节性类固醇，特别是16α-溴表雄酮的半水合物

Country Status (22)

Country Link
EP (1) EP1163256B1 (enExample)
JP (1) JP2002540119A (enExample)
KR (2) KR20070007394A (enExample)
CN (1) CN1243767C (enExample)
AP (1) AP2001002285A0 (enExample)
AT (1) ATE259825T1 (enExample)
AU (1) AU781997B2 (enExample)
BR (1) BR0009476A (enExample)
CA (1) CA2365081A1 (enExample)
CZ (1) CZ20013420A3 (enExample)
DE (1) DE60008353T2 (enExample)
DK (1) DK1163256T3 (enExample)
ES (1) ES2215631T3 (enExample)
HK (1) HK1046002B (enExample)
HU (1) HUP0203429A3 (enExample)
IL (1) IL144916A0 (enExample)
NO (2) NO320801B1 (enExample)
NZ (1) NZ513803A (enExample)
OA (1) OA11850A (enExample)
PT (1) PT1163256E (enExample)
RU (2) RU2417792C2 (enExample)
WO (1) WO2000056757A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070129282A1 (en) 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
EP1228083A2 (en) 1999-09-30 2002-08-07 Hollis-Eden Pharmaceuticals Inc. Therapeutic treatment of androgen receptor driven conditions
US7241753B2 (en) 2000-02-25 2007-07-10 Loria Roger M Method of treatment of prostate cancer
EP1372664A1 (en) 2001-03-01 2004-01-02 Hollis-Eden Pharmaceuticals Inc. Use of certain steroids for treatment of blood cell deficiencies
FR2829697B1 (fr) * 2001-09-14 2004-03-19 Mayoly Spindler Lab Derives 7-hydroxyles et 7-cetoniques des hormones steroides 3 beta-hydroxylees pour le traitement des maladies inflammatoires ou fonctionnelles de l'intestin
US20040138187A1 (en) * 2002-08-28 2004-07-15 Reading Christopher L. Therapeutic treatment methods
GB0304927D0 (en) 2003-03-04 2003-04-09 Resolution Chemicals Ltd Process for the production of tibolone
RU2356555C2 (ru) * 2003-12-26 2009-05-27 Ниссан Кемикал Индастриз, ЛТД Антинейтрофильное средство
MD4009C2 (ro) * 2008-07-15 2010-08-31 Институт Химии Академии Наук Молдовы Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos
CN104072564B (zh) * 2013-03-28 2016-08-17 广州市赛普特医药科技股份有限公司 2β,3α,5α-三羟基-雄甾-6-酮及其制备方法与用途
CN106565654B (zh) * 2016-10-14 2018-08-31 云南中烟工业有限责任公司 一种从白云参中提取的新型黄酮类化合物、其制备方法及其用途
BR112020021278A2 (pt) * 2018-06-01 2021-01-26 Société des Produits Nestlé S.A. butirato dietário
US10836788B2 (en) 2019-02-05 2020-11-17 SD Chem, Inc. Aqueous suspension compositions, formulations, and water dispersible dry compositions comprising 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-ketone and hydrates, derivatives, and analogs thereof
AU2020398693A1 (en) * 2019-12-05 2022-04-28 Société des Produits Nestlé S.A. Dietary butyrate
CN114907333B (zh) * 2022-05-11 2023-07-04 中国人民解放军军事科学院军事医学研究院 环丙甲酰胺衍生物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH197784A (de) * 1934-05-25 1938-05-15 Schering Kahlbaum Ag Verfahren zu Darstellung von D5,6-trans-Androstendiol-3,17.
ES8706717A1 (es) * 1983-08-02 1987-07-01 Research Corp Metodo de preparar esteroides
NL194728C (nl) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan.
US4910226A (en) * 1987-04-29 1990-03-20 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
JPH0289327A (ja) * 1988-09-27 1990-03-29 Matsushita Electron Corp 銀ペースト塗布装置
US5837269A (en) * 1989-09-25 1998-11-17 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
IE60458B1 (en) * 1989-10-26 1994-07-13 Elan Corp Plc Enhanced bioavailability adsorbates

Also Published As

Publication number Publication date
NZ513803A (en) 2004-06-25
EP1163256A1 (en) 2001-12-19
HUP0203429A2 (hu) 2003-01-28
CN1243767C (zh) 2006-03-01
KR100717897B1 (ko) 2007-05-14
DE60008353T2 (de) 2005-09-08
NO20014588D0 (no) 2001-09-21
RU2417792C2 (ru) 2011-05-10
ATE259825T1 (de) 2004-03-15
JP2002540119A (ja) 2002-11-26
HUP0203429A3 (en) 2004-07-28
CN1355809A (zh) 2002-06-26
RU2001128881A (ru) 2003-09-27
CA2365081A1 (en) 2000-09-28
NO20056167L (no) 2001-11-21
RU2295534C2 (ru) 2007-03-20
DE60008353D1 (de) 2004-03-25
HK1046002A1 (en) 2002-12-20
KR20020003217A (ko) 2002-01-10
AP2001002285A0 (en) 2001-12-31
DK1163256T3 (da) 2004-06-28
WO2000056757A1 (en) 2000-09-28
EP1163256B1 (en) 2004-02-18
IL144916A0 (en) 2002-06-30
BR0009476A (pt) 2002-02-19
AU3919000A (en) 2000-10-09
KR20070007394A (ko) 2007-01-15
CZ20013420A3 (cs) 2002-04-17
AU781997B2 (en) 2005-06-23
NO320801B1 (no) 2006-01-30
PT1163256E (pt) 2004-07-30
ES2215631T3 (es) 2004-10-16
NO20014588L (no) 2001-11-21
RU2006133273A (ru) 2008-03-27
OA11850A (en) 2006-03-06

Similar Documents

Publication Publication Date Title
US8106036B2 (en) Pharmaceutical compositions-4
US8022234B2 (en) Compounds and compositions
CN1243767C (zh) 免疫调节性类固醇,特别是16α－溴表雄酮的半水合物
US8541600B2 (en) 11-aza, 11-thia and 11-oxa sterol compounds and compositions
CA2439687A1 (en) Use of certain steroids for treatment of blood cell deficiencies
EP1422234A2 (en) Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone
AU2005211675B2 (en) Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone
HK1097551A (en) Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone
CN1837231A (zh) 免疫调节性类固醇，特别是16α－溴表雄酮的半水合物
MXPA01009624A (en) Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140323